BRPI0409409A - métodos para tratar doenças proliferativas e para monitorar a eficácia de tratamento de doenças proliferativas - Google Patents

métodos para tratar doenças proliferativas e para monitorar a eficácia de tratamento de doenças proliferativas

Info

Publication number
BRPI0409409A
BRPI0409409A BRPI0409409-3A BRPI0409409A BRPI0409409A BR PI0409409 A BRPI0409409 A BR PI0409409A BR PI0409409 A BRPI0409409 A BR PI0409409A BR PI0409409 A BRPI0409409 A BR PI0409409A
Authority
BR
Brazil
Prior art keywords
proliferative diseases
treating proliferative
treating
effectiveness
monitoring
Prior art date
Application number
BRPI0409409-3A
Other languages
English (en)
Inventor
Ping Hu
Yingqi Karen Wang
David Bryant Batt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0409409A publication Critical patent/BRPI0409409A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MéTODOS PARA TRATAR DOENçAS PROLIFERATIVAS E PARA MONITORAR A EFICáCIA DE TRATAMENTO DE DOENçAS PROLIFERATIVAS". A presente invenção refere-se às fosfoproteínas úteis como biomarcadores para identificar e tratar pacientes que sofrem de doenças caracterizadas por uma via de sinalização de MAP cinase aberrante, por exemplo, doenças proliferativas como certos cânceres que monitoram a eficácia do tratamento de pacientes tendo a doença, administrando inibidores de Raf cinase e diagnosticando a doença nos pacientes.
BRPI0409409-3A 2003-04-14 2004-04-13 métodos para tratar doenças proliferativas e para monitorar a eficácia de tratamento de doenças proliferativas BRPI0409409A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46272303P 2003-04-14 2003-04-14
PCT/EP2004/003877 WO2004090545A2 (en) 2003-04-14 2004-04-13 Methods for treating proliferative diseases and for monitoring the effectiveness of treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
BRPI0409409A true BRPI0409409A (pt) 2006-04-25

Family

ID=33159860

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409409-3A BRPI0409409A (pt) 2003-04-14 2004-04-13 métodos para tratar doenças proliferativas e para monitorar a eficácia de tratamento de doenças proliferativas

Country Status (9)

Country Link
US (1) US20070099250A1 (pt)
EP (1) EP1616191A2 (pt)
JP (1) JP2006525962A (pt)
CN (1) CN1784602A (pt)
AU (1) AU2004227103A1 (pt)
BR (1) BRPI0409409A (pt)
CA (1) CA2522333A1 (pt)
MX (1) MXPA05011074A (pt)
WO (1) WO2004090545A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
AU2005309019A1 (en) * 2004-11-24 2006-06-01 Novartis Ag Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors
EP1863491A1 (en) * 2005-02-25 2007-12-12 Novartis AG Pharmaceutical combination of bcr-abl and raf inhibitors
EP1982174A4 (en) * 2006-01-27 2009-05-06 Univ George Mason EYES LIQUID MARKER
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2239337A1 (en) * 2009-04-10 2010-10-13 PamGene B.V. Method for the prediction of the response of locally advanced rectal cancer to chemoradiotherapy
US8617836B2 (en) 2009-04-10 2013-12-31 Pamgene B.V. Method for predicting the response of locally advanced rectal cancer to chemoradiotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10017480A1 (de) * 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
US7199137B2 (en) * 2000-09-21 2007-04-03 Smithkline Beecham Plc Imidazole derivatives as Raf kinase inhibitors

Also Published As

Publication number Publication date
MXPA05011074A (es) 2005-12-12
US20070099250A1 (en) 2007-05-03
CA2522333A1 (en) 2004-10-21
EP1616191A2 (en) 2006-01-18
AU2004227103A1 (en) 2004-10-21
WO2004090545A2 (en) 2004-10-21
CN1784602A (zh) 2006-06-07
WO2004090545A3 (en) 2005-08-11
JP2006525962A (ja) 2006-11-16

Similar Documents

Publication Publication Date Title
Moreau et al. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model
Ferreira-Gomes et al. Assessment of movement-evoked pain in osteoarthritis by the knee-bend and CatWalk tests: a clinically relevant study
Mousavi et al. Schwann cell transplantation exerts neuroprotective roles in rat model of spinal cord injury by combating inflammasome activation and improving motor recovery and remyelination
Van Loon et al. Intra‐articular opioid analgesia is effective in reducing pain and inflammation in an equine LPS induced synovitis model
BRPI0606902A2 (pt) composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica
BRPI0415397A (pt) métodos e reagentes para o tratamento de desordens imunoinflamatórias
MX2007010064A (es) Sistema y metodo de prediccion de respuesta al tratamiento neurologico, usando el electroencefalograma.
WO2008070137A3 (en) Interferon alpha-induced pharmacodynamic markers
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EP1689288A4 (en) IMMUNOADSORBENT BLOOD TESTS FOR EVALUATING PAROXYSMAL BRAIN DISCHARGES
BRPI0407747A (pt) agente terapêutico para lesão à medula espinhal compreendendo antagonista de interleucinas-6
GB2490084A (en) Methods and compositions to treat hemorrhagic conditions of the brain
ATE451475T1 (de) Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben
Pattij et al. Dopaminergic modulation of impulsive decision making in the rat insular cortex
Steele III et al. Neurotensin NTS1 and NTS2 receptor agonists produce anxiolytic-like effects in the 22-kHz ultrasonic vocalization model in rats
Sebastian et al. Robust training attenuates TBI-induced deficits in reference and working memory on the radial 8-arm maze
Li et al. Trigeminal nerve injury‐induced thrombospondin‐4 up‐regulation contributes to orofacial neuropathic pain states in a rat model
ES2385138T3 (es) Modelo de roedor de enfermedad para dolor muscular crónico
BRPI0409409A (pt) métodos para tratar doenças proliferativas e para monitorar a eficácia de tratamento de doenças proliferativas
MX2010010799A (es) Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea.
Ris et al. Sexual dimorphisms in the effect of low‐level p25 expression on synaptic plasticity and memory
Kuts et al. A middle cerebral artery occlusion technique for inducing post-stroke depression in rats
PT1900365E (pt) Compostos do tipo canabinóide e o seu uso para o tratamento de dermatites
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
McCarson et al. Amitriptyline prevents thermal hyperalgesia and modifications in rat spinal cord GABAB receptor expression and function in an animal model of neuropathic pain

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.